Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by APG Asset Management N.V.

APG Asset Management N.V. reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 31.8% in the second quarter, HoldingsChannel.com reports. The fund owned 257,315 shares of the company’s stock after selling 119,803 shares during the quarter. APG Asset Management N.V.’s holdings in Neurocrine Biosciences were worth $33,053,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently made changes to their positions in NBIX. Mather Group LLC. acquired a new position in Neurocrine Biosciences during the 1st quarter valued at approximately $26,000. RFP Financial Group LLC boosted its holdings in shares of Neurocrine Biosciences by 346.5% during the first quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock valued at $26,000 after acquiring an additional 149 shares during the period. Ashton Thomas Private Wealth LLC acquired a new position in shares of Neurocrine Biosciences during the second quarter valued at $28,000. Innealta Capital LLC bought a new position in shares of Neurocrine Biosciences during the second quarter worth about $30,000. Finally, New Covenant Trust Company N.A. acquired a new stake in shares of Neurocrine Biosciences in the 1st quarter worth about $32,000. 92.59% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have commented on NBIX. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research report on Monday, September 16th. Oppenheimer increased their price objective on Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Robert W. Baird lifted their target price on Neurocrine Biosciences from $157.00 to $180.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Piper Sandler upgraded Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $131.00 to $159.00 in a research report on Thursday, August 29th. Finally, Citigroup raised their price target on Neurocrine Biosciences from $150.00 to $158.00 and gave the company a “neutral” rating in a report on Friday, August 2nd. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $162.20.

Insider Buying and Selling at Neurocrine Biosciences

In other news, insider Julie Cooke sold 10,000 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $140.19, for a total value of $1,401,900.00. Following the transaction, the insider now directly owns 18,202 shares of the company’s stock, valued at $2,551,738.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Neurocrine Biosciences news, Director William H. Rastetter sold 14,250 shares of Neurocrine Biosciences stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $146.69, for a total value of $2,090,332.50. Following the completion of the sale, the director now directly owns 37,491 shares in the company, valued at $5,499,554.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Julie Cooke sold 10,000 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $140.19, for a total transaction of $1,401,900.00. Following the transaction, the insider now owns 18,202 shares in the company, valued at approximately $2,551,738.38. The disclosure for this sale can be found here. Insiders sold 71,798 shares of company stock valued at $10,676,096 in the last quarter. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Trading Down 0.8 %

NASDAQ:NBIX opened at $115.06 on Friday. The business’s fifty day moving average price is $136.11 and its 200 day moving average price is $137.61. The firm has a market capitalization of $11.58 billion, a price-to-earnings ratio of 31.70 and a beta of 0.37. Neurocrine Biosciences, Inc. has a 1-year low of $103.63 and a 1-year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). The company had revenue of $590.20 million during the quarter, compared to analysts’ expectations of $545.98 million. Neurocrine Biosciences had a return on equity of 14.86% and a net margin of 16.00%. Neurocrine Biosciences’s revenue for the quarter was up 30.4% compared to the same quarter last year. During the same period last year, the company earned $0.95 earnings per share. Equities analysts forecast that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.